Peptide Comparison
AHK-Cu vs Palmitoyl Dipeptide-6
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu and Palmitoyl Dipeptide-6 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Palmitoyl Dipeptide-6 | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Cosmetic lipopeptide (retinol-mimic) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Activates retinoid-responsive genes without retinoid irritation |
| Route | Topical | Topical |
| Half-life | Topical (no systemic) | Topical |
| Dosage (research) | Topical 0.01-0.1% | Topical 1-3% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 5 indexed | — |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Skin irritation; theoretical copper issues | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Palmitoyl Dipeptide-6?
AHK-Cu and Palmitoyl Dipeptide-6 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.
What is the difference between AHK-Cu and Palmitoyl Dipeptide-6?
AHK-Cu is classed as Copper tripeptide (cosmetic); Palmitoyl Dipeptide-6 is classed as Cosmetic lipopeptide (retinol-mimic). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Palmitoyl Dipeptide-6, Activates retinoid-responsive genes without retinoid irritation. Reported half-life: AHK-Cu, Topical (no systemic); Palmitoyl Dipeptide-6, Topical. Routes in published studies: AHK-Cu, Topical; Palmitoyl Dipeptide-6, Topical.
Which has stronger evidence, AHK-Cu or Palmitoyl Dipeptide-6?
AHK-Cu and Palmitoyl Dipeptide-6 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies. Palmitoyl Dipeptide-6 is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page.
Which is more accessible, AHK-Cu or Palmitoyl Dipeptide-6?
Neither AHK-Cu nor Palmitoyl Dipeptide-6 is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Palmitoyl Dipeptide-6, Cosmetic.
Are AHK-Cu and Palmitoyl Dipeptide-6 ever combined?
AHK-Cu and Palmitoyl Dipeptide-6 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…